Background-Common genetic variants in the insulin receptor substrate 1 (IRS1) gene have been recently associated with insulin resistance and hyperinsulinemia. We examined whether the best-associated variant modifies the long-term changes in insulin resistance and body weight in response to weight-loss diets in Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial. Methods and Results-We genotyped IRS1 rs2943641 in 738 overweight adults (61% were women) who were randomly assigned to 1 of 4 diets varying in macronutrient contents for 2 years. We assessed the progress in fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR) and weight loss by genotypes. At 6 months, participants with the risk-conferring CC genotype had greater decreases in insulin (Pϭ0.009), HOMA-IR (Pϭ0.015), and weight loss (Pϭ0.018) than those without this genotype in the highest-carbohydrate diet group whereas an opposite genotype effect on changes in insulin and HOMA-IR (PՅ0.05) was observed in participants assigned to the lowest-carbohydrate diet group. No significant differences were observed across genotypes in the other 2 diet groups.
I nsulin resistance, the most common metabolic disorder associated with obesity, is a major risk factor for type 2 diabetes mellitus and cardiovascular disease. 1 Besides the important contribution of environmental factors such as diet and physical activity, genetic variants that influence insulin signaling also play a key role in insulin resistance. 2 Identifying the gene-lifestyle interactions on insulin resistance may clarify the mechanisms underlying the development of type 2 diabetes and cardiovascular disease and provide effective strategies for disease prevention.
Clinical Perspective on p •••
A large body of evidence has shown that dietary interventions are beneficial in promoting weight loss and improving insulin action though there is still extensive debate about the effectiveness of different diets varying in macronutrient components, especially fat and carbohydrates. [3] [4] [5] Emerging data also indicate that genetic background may modify insulin action in response to dietary interventions. 6 The insulin receptor substrate 1 (IRS1) gene encodes IRS1 which is a major mediator between the insulin receptor and phosphatidylinositol 3-kinase (PI3K) in the insulin signaling pathway. 7, 8 A recent genome-wide association study identified a common genetic variant rs2943641 associated with insulin resistance, hyperinsulinemia, and type 2 diabetes mellitus. 9 A very recent intervention trial reported that IRS1 gene variation might modulate the effect of a low-fat and high-carbohydrate diet on insulin sensitivity. 10 However, the sample size of that study was small (59 healthy whites).
In the 2-year Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) trial, 11 the longest and largest comparator trial on weight-loss diets so far, 4 reduced-calorie diets with different compositions of macronutrients resulted in similar weight loss in 811 overweight participants. The diets also improved fasting insulin levels and insulin resistance. In the present study, we aimed to test whether the newly identified IRS1 variant rs2943641 modifies the effects of weight-loss diets on the long-term changes in body weight, fasting insulin, and insulin resistance over the intervention.
Methods

The Preventing Overweight Using Novel Dietary Strategies (POUNDS LOST) Trial
The POUNDS LOST trial is a 2-year randomized, clinical trial to compare the effects of energy-reduced diets with different compositions of fat, protein, and carbohydrate on body weight. The study design, methods, and primary results have been described in detail elsewhere. 11 Briefly, a total of 811 overweight and obese subjects (25 kg/m 2 Յbody mass indexՅ40 kg/m 2 ) aged 30 to 70 years were randomly assigned to 1 of 4 diets; the target percentages of energy derived from fat, protein, and carbohydrate in the 4 diets were 20%, 15%, and 65%; 20%, 25%, and 55%; 40%, 15%, and 45%; and 40%, 25%, and 35%. Major criteria for exclusion were the presence of diabetes mellitus or unstable cardiovascular disease, the use of medications that affect body weight, and insufficient motivation. Random assignments to 1 of 4 diet groups were generated by the data manager at the coordinating center on request of a study dietitian after eligibility of a participant was confirmed. The diets consisted of similar foods and met guidelines for cardiovascular health, and carbohydrate-rich foods were used having a lower glycemic index. After 2 years, 80% of the participant (nϭ645) completed the trial. The participants flow diagram has been published previously (online-only Data Supplement Figure I ). 11 The study was approved by the human subjects committee at the Harvard School of Public Health and Brigham and Women's Hospital, Boston, MA, by the Pennington Biomedical Research Center of the Louisiana State University System, Baton Rouge, LA, and by a data and safety monitoring board appointed by the National Heart, Lung, and Blood Institute. All participants gave written informed consent.
Participants
A total of 738 participants with DNA sample available were included in the current study (91% of the participants in the POUNDS LOST trial). Among them, 61% were women, 80% were white, 15% were black, 3% were Hispanic, and 2% were Asian or other ethnic groups by self report. Consistent with the entire POUNDS LOST trial, the meanϮSD age was 51Ϯ9 years and the mean BMI was 32.7Ϯ3.9 kg/m 2 . There was no significant difference in the basic characteristics between the participants with and without DNA samples.
Measurements
Body weight was measured in the morning before breakfast on 2 days at baseline, 6 months, and 2 years. Dietary intake was assessed in a random sample of 50% of the participants, by a review of the 5-day diet record at baseline, and by 24-hour recall during a telephone interview on 3 nonconsecutive days at 6 months and at 2 years. Fasting blood samples, 24-hour urine samples, and measurement of resting metabolic rate were obtained on 1 day, and blood pressure was measured on 2 days at baseline, 6 months, and 2 years. Levels of serum lipids, glucose, and insulin were measured at the clinical laboratory at the Pennington Biomedical Research Center. 
Genotyping
DNA was extracted from the buffy coat fraction of centrifuged blood using the QIAmp Blood Kit (Qiagen, Chatsworth, CA). Single-nucleotide polymorphism (SNP) rs2943641, the best-associated variant with type 2 diabetes mellitus and insulin resistance in IRS1 locus, 9 was genotyped using the OpenArray SNP Genotyping System (BioTrove, Woburn, MA). The genotype success rate was 99%. Replicate quality control samples (10%) were included and genotyped with Ͼ99% concordance. The allele frequency in all participants or in white was in Hardy-Weinberg equilibrium (PϾ0.05).
Statistical Analysis
The primary end points for this study were changes in fasting insulin, insulin resistance (estimated by HOMA-IR) and body weight over the intervention. Insulin and HOMA-IR were log-transformed before analysis. General linear models (PROC GLM) for continuous variables and 2 test (PROC FREQ) for categorical variables were applied for the comparison according to genotype groups at baseline. We compared the changes in the primary end points, biomarkers of adherence, and nutrient intakes across genotype groups at 6 months and 2 years using general linear models. To test for interactions, we examined genotype, intervention (overall 4 diet groups), and genotype-by-intervention interactions as independent predictors of changes in the primary end points, adjusted for age, sex, ethnicity, and the baseline value for the respective outcome trait, in the general linear models. As the majority of the participants were white (80%), we also examined the genotype effects and interactions in white participants in sensitivity analyses. Linear mixed models (PROC MIXED) using variance components structure, were used to test the genotype effect on the trajectory of changes in weight, fasting insulin, and HOMA-IR in the participants who provide measurements at baseline, 6 months, and 2 years in each of 4 diet groups over the 2-year intervention by including genotype-by-time interaction terms. Secondary analyses were performed to compare the 2 extreme carbohydrate diets (the highest-carbohydrate diet versus the lowestcarbohydrate diet) by the genotype. Consistent with the previous reported association between IRS1 rs2943641 and insulin resistance, 9 both additive and dominant inheritance models were tested. All reported P values are nominal and 2-side, and a P value of 0.05 was considered statistically significant. Bonferroni adjustment was used to adjust P values for multiple tests for each trait at each time point. We used Quanto 1.2.4 (University of Southern California, Los Angeles, CA; http://hydra.usc.edu.gxe) to estimate the detectable effect sizes of genotype-by-diet (2 extreme diets) interactions. The study had 80% power to detect gene-diet interaction effect sizes of 2.6 and 3.4 kg for weight loss, 0.21 and 0.22 log-transformed unit for changes in fasting insulin, and 0.24 and 0.24 log-transformed unit for changes in HOMA-IR at 6 months and 2 years, respectively, under an additive model. Statistical analyses were performed with SAS version 9.1 (SAS Institute Inc, Cary, NC). Table 1 shows the baseline characteristics of participants according to the IRS1 rs2943641 genotype. The genotype frequencies were similar between sexes and across the 4 diet groups whereas they differed among ethnic groups (Pϭ0.01). After adjustment for age, sex and ethnicity, the C allele of rs2943641 was signifi-cantly associated with increased fasting insulin and HOMA-IR (both ␤ϭ0.09Ϯ0.03, Pϭ0.005), consistent with previous reports. 9 We also found associations of this SNP with systolic and diastolic blood pressures (Pϭ0.08 and 0.005, respectively), which was attenuated by further adjustment for fasting insulin (Pϭ0.15 and 0.02, respectively). No other differences in baseline characteristics across the genotype were observed.
Results
Baseline Characteristics
Nutrient Intake and Biomarkers of Adherence by the IRS1 Genotype
Consistent with the entire POUNDS LOST trial, the reported dietary intakes (total energy, fat, protein, and carbohydrate) and changes in biomarker of adherence (urinary nitrogen and respiratory quotient) confirmed that participants modified their intake of macronutrients in the *The targeted percentages of energy derived from fat, protein, and carbohydrate from group 1 to group 4 were 20%, 15%, and 65%; 20%, 25%, and 55%; 40%, 15%, and 45%; and 40%, 25%, and 35%.
†These variables were log-transformed before analysis.
direction of the intervention, although the targets were not fully achieved. The mean values of nutrient intakes and biomarkers of adherence at 6 months and at 2 years were similar across IRS1 rs2943641 genotype in each of the 4 diet groups (all PϾ0.05; Data are expressed as meanϮSD. IRS1 indicates the insulin receptor substrate 1 gene. *Data were included for 79 to 85 participants per diet group at 6 mo and 38 to 45 at 2 y. †Data were included for 127 to 141 participants per diet group at 6 mo and 85 to 103 at 2 y. ‡Data were included for 145 to 155 participants per diet group at 6 mo and 103 to 124 at 2 y.
fasting insulin (P add ϭ0.024, P dom ϭ0.011), and HOMA-IR (P add ϭ0.025, P dom ϭ0.013), adjusted for age, sex, ethnicity, and the baseline value for the respective outcome trait (Table 3) . Participants with the CC genotype had greater weight loss than those without this genotype in the highest-carbohydrate diet group (P add ϭ0.015, P dom ϭ0.018) whereas no significant genotype effects were observed in the other 3 diet groups (all PϾ0.14). Participants with the CC genotype had greater decreases in insulin levels than those without this genotype in the highest-carbohydrate diet group (P add ϭ0.006, P dom ϭ0.009) whereas an opposite genotype effect was observed in participants assigned to the lowest-carbohydrate diet group (P add ϭ0.098, P dom ϭ0.05). No significant differences were observed across the IRS1 genotypes in the other 2 diet groups (all PϾ0.14). Moreover, among participants in the highest-carbohydrate diet group, after further adjustment for weight loss, the genotype effect on changes in insulin (Pϭ0.04) remained significant whereas the genotype effect on weight loss became nonsignificant after further adjustment for changes in insulin or HOMA-IR (PϾ0.36). The results for changes in HOMA-IR were similar to those for fasting insulin (Table 3 , Pϭ0.05 after further adjustment for weight loss). After adjustment for multiple tests for each trait (4 within-diet tests; significant P value was 0.0125 [0.05/4]), the genotype effect on changes in fasting insulin and HOMA-IR in the highest-carbohydrate diet group remained significant. Because the IRS1 rs2943641 genotype was associated with baseline fasting insulin and HOMA-IR, we further examined the interactions between baseline levels of insulin or HOMA-IR (tertiles) and the 4 diet groups on changes in fasting insulin or HOMA-IR. There were no significant results (all P for interaction Ͼ0.37). Our data suggest that the observed interactions were less likely to be driven by baseline levels of insulin or HOMA-IR.
At 2 years, most participants regained body weight and there was no significant interaction or genotype effect on weight loss. For changes in fasting insulin and HOMA-IR, the genotype-diet interactions were attenuated, with a marginal significance under the dominant genetic model (Pϭ0.068 and 0.075, respectively). The genotype effect also became weaker but remained significant in the highest-carbohydrate diet group (Pϭ0.017 and 0.023, respectively). However, the results did not remain statistical significance after adjustment for multiple tests for each trait (n tests ϭ4).
In the sensitivity analyses including only white participants, the results were similar. At 6 months, there were significant interactions between genotype and diet on changes in weight, insulin, and HOMA-IR under both additive and Data are expressed as meanϮSE after adjustment for age, sex, ethnicity, and the baseline value for the respective outcome trait. HOMA-IR indicates homeostasis model assessment of insulin resistance; IRS1, the insulin receptor substrate 1 gene; P add , P value under an additive model; P dom , P value under a dominant model. *Data were included for 69 to 84 (CC), 65 to 73 (CT), and 18 to 23 (TT) participants per diet group at 6 mo (total nϭ661), and 56 to 73 (CC), 55 to 68 (CT), and 17 to 22 (TT) participants per diet group at 2 y (total nϭ600).
†Data were included for 61 to 75 (CC), 62 to 68 (CT), and 17 to 22 (TT) participants per diet group at 6 mo (total nϭ606) and 48 to 61 (CC), 50 to 64 (CT), and 14 to 18 (TT) participants per diet group at 2 y (total nϭ523); these 2 variables were log-transformed before analysis.
dominant genetic models (all PϽ0.05). At 2 years, the results were attenuated but with the same trend.
Trajectory of Changes in Weight, Fasting Insulin, and HOMA-IR
We then used linear mixed models to assess the genotype by time effect over the 2-year intervention and found significant interactions between genotype and intervention time on changes in fasting insulin (P add ϭ0.045, P dom ϭ0.005) and HOMA-IR (P add ϭ0.05, P dom ϭ0.009) among participants in the highest-carbohydrate diet group; in which participants with the CC genotype had a greater improvement of fasting insulin and insulin resistance than those without this genotype across 2-year intervention (Figure 1) . These results did not change after further adjustment for weight loss. However, we did not find the genotype-time interactions on weight loss in this diet group (P add ϭ0.86, P dom ϭ0.52). The genotype-time interactions were not observed in other diet groups (onlineonly Data Supplement Figure II , all PϾ0.31).
Effects of the Highest-Carbohydrate and Lowest-Carbohydrate Diets by the IRS1 Genotype
Given the opposite effects of the IRS1 rs2943641 genotype in response to the highest-carbohydrate and lowest-carbohydrate diets, we then tested the effects of these 2 extreme carbohydrate diets by the IRS1 rs2943641 genotype as secondary analyses (Figure 2 ). For participants with the CC genotype, the highestcarbohydrate diet decreased weight, fasting insulin, and HOMA-IR more than the lowest-carbohydrate diet (Pϭ0.08, 0.016 and 0.009, respectively). In contrast, the lowestcarbohydrate diet decreased weight, fasting insulin, and HOMA-IR more than the highest-carbohydrate diet among participants without CC genotype (Pϭ0.24, 0.03, and 0.05, respectively). At 2 years, the diet effects were attenuated ( Figure  2 ). After adjustment for multiple comparisons (2 within-genotype group [CC and CTϩTT genotypes] tests for each trait at each time point; significant P value was 0.025 [0.05/2]), the diet effect on changes in fasting insulin and HOMA-IR at 6 months among participants with the CC genotype remained statistical significance.
Discussion
In this study, we examined the genotype effect of the IRS1 variant rs2943641 on weight loss and insulin resistance in response to 4 weight-loss diets varying in macronutrient components in the POUNDS LOST trial. We found potential gene-intervention interactions on improvement of fasting insulin and HOMA-IR at 6 month and 2 years of follow-up. Participants with the CC genotype showed greater improvement of insulin resistance in response to the highestcarbohydrate diet than those without this genotype.
At baseline, we confirmed the reported association between the IRS1 rs2943641 C allele and insulin resistance and hyperinsulinemia. 9 We observed parallel gene-diet interactions on weight loss and improvement of insulin resistance at 6 months. The genotype effect on improvement of fasting insulin and HOMA-IR remained after adjustment for weight loss. Our results suggest that this effect on the changes in insulin resistance might be independent of weight loss though weight loss has been considered as a cornerstone for improving IR. 3 In contrast, the genotype effect on weight loss diminished after Figure 1 . Genotype effect of IRS1 rs2943641 on trajectory of changes in weight, fasting insulin, and HOMA-IR in participants assigned to the highest-carbohydrate diet over 2 Years. A, Changes in weight. Data were included for 187, 162, and 158 participants at baseline, 6 months, and 2 years, respectively. B, Changes in fasting insulin. Data were included for 185, 150, and 135 participants at baseline, 6 months, and 2 years, respectively. C, Changes in HOMA-IR. Data were included for 185, 150, and 135 participants at baseline, 6 months, and 2 years, respectively. Data are expressed as meanϮSE after adjustment for age, sex, and ethnicity. P values were tested for the interaction between genotype and intervention time. Insulin and HOMA-IR were log-transformed before analysis. HOMA-IR indicates homeostasis model assessment of insulin resistance. adjustment for changes in fasting insulin or HOMA-IR, suggesting that improvement in insulin resistance may influence weight loss. We have carefully adjusted for the covariates correlated with the genotype such as ethnicity and baseline levels of fasting insulin or HOMA-IR in our analysis. The sensitivity analysis in white participants showed similar results. These analyses indicate that our findings are unlikely to be due to confounding. In addition, there was no interaction between baseline levels of fasting insulin/HOMA-IR and diets.
As expected, the gene-diet interactions on weight loss and insulin resistance were largely attenuated at 2 years. This may be due to diminished adherence that occurred between 6 months and 2 years in the POUNDS LOST trial, 11 similar to other weight-loss trials. [13] [14] [15] [16] [17] A relatively large number of dropouts (nϭ179) at 2 years may also reduce the statistical power. Nonetheless, we still observed that participants with the IRS1 rs2943641 CC genotype showed a greater improvement of insulin resistance compared to those without this genotype, assigned to the highest-carbohydrate diet over the 2-year period. This result indicates a stable and long-term effect of the IRS1 rs2943641 CC genotype on improvement of insulin resistance in response to a weight-loss diet with high carbohydrate. However, it is difficult to tease out which macronutrient is responsible for the observed interactions because the percentages of fat, carbohydrates, and protein changed simultaneously. Because there was little energy difference (Ϸ2%, based on the assessment of diet recall data and urinary nitrogen exertion) derived from protein among the diet groups, 18, 19 increased carbohydrate as percentage of energy intake mostly reflects decreased fat intake. Thus, either dietary fat or carbohydrates may modulate the effect of the IRS1 rs2943641. In addition, it should be noted that high-quality carbohydrate-rich foods (low glycemic index) were used in this intervention study.
It is interesting that participants with the IRS1 rs2943641 CC genotype associated with a higher degree of insulin resistance 9 but showed greater improvement of insulin resistance than those with other genotypes in response to the highcarbohydrate/low-fat diet. Our findings are consistent with a recent study in which healthy subjects with a risk allele of IRS1 rs1801278 (G972R) for insulin resistance also showed more improvement in insulin sensitivity after eating a highcarbohydrate diet compared with the fat-rich diets. 10 The potential mechanisms underlying these findings are unknown but might be related to lipid-induced insulin resistance. 20 Previous studies have shown that long-term high-fat diets and increased plasma free fatty acid levels impair insulin signaling by alteration in tyrosine/serine phosphorylation of IRS1, leading to decreased activation of IRS1-associated PI3K activity. [21] [22] [23] [24] Thus, it is possible that the activation of IRS1-associated PI3K activity may be enhanced in the IRS1 rs2943641 CC subjects when they consume a low-fat and high-carbohydrate diet, in comparison with subjects with other genotypes. However, although it has been suggested that IRS1 rs2943641 is associated with IRS1-associated PI3K activity, 9 it is unclear whether this variant affects phosphorylation in key residues of IRS1. The precise mechanisms responsible for the interaction between IRS1 gene variation and diet on insulin action remain to be further clarified.
To the best of our knowledge, this is the first study to date to assess the relationship of gene-diet interactions to improvement of insulin resistance with weight loss in a large and long-term randomized trial. Our data may provide novel information for the development of effective dietaryintervention strategies based on genetic background. However, several limitations of this study warrant consideration. Insulin resistance was assessed by HOMA-IR rather than by using euglycemic glucose clamp technique because it was not feasible to apply such a technique in this large population- Figure 2 . Effect of the highest-carbohydrate and the lowestcarbohydrate diets on changes in weight (A), fasting insulin (B), and HOMA-IR (C) by IRS1 genotypes at 6 months and 2 years. Data are expressed as meanϮSE, and P values are for comparisons between the 2 extreme diet groups after adjustment for age, sex, and ethnicity. Insulin and HOMA-IR were logtransformed before analysis. HOMA-IR indicates homeostasis model assessment of insulin resistance.
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based trial. Because the adherence to various diets declined after 6 months, the power to detect a long-term genotype effect in response to the real difference in macronutrients intake among the diet groups was reduced. Although it is the largest weight-loss trial so far, this study may be underpowered for detecting modest interactions and associations. Because the primary end points (insulin and HOMA-IR) and the repeated measurement at 6 months and 2 years were correlated, it is too conservative to treat them as independent analyses, and overadjustment for multiple comparisons may increase the type 2 error and the risk of false-negative findings. We therefore controlled for multiple tests for each trait at each time point. Of note, our primary analysis was based on an a priori hypothesis driven by previous studies, 9, 10 which is biologically plausible. Most of the participants (80%) in our study are white, and it remains to be determined whether our findings could be generalized to other ethnic groups. In addition, the participants of our study are overweight or obese; therefore, further studies are warranted to investigate whether our findings are applicable in general populations. Because the C-allele of this SNP was common in the general populations (frequency ϭ0.63, 0.92, and 0.77 for whites, East Asians and blacks, HapMap CEU, HCB, and YRI data, respectively), this variant could be a proxy of genetic background for choosing diets varying in macronutrients in prevention of insulin resistance and cardiovascular disease.
In conclusion, we found that the IRS1 variant rs2943641 modified insulin resistance response to weight-loss diets in a 2-year randomized trial. Participants with the IRS1 rs2943641 CC genotype might obtain more benefits in weight loss and improvement of insulin resistance than those without this genotype in response to a high-carbohydrate/low-fat diet. These novel findings provide supportive evidence for the notion of a personalized nutrition intervention in preventing diseases related to obesity and insulin resistance, such as type 2 diabetes mellitus and cardiovascular disease.
